Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Int J Exp Pathol ; 87(5): 393-403, 2006 Oct.
Article de Anglais | MEDLINE | ID: mdl-16965567

RÉSUMÉ

Beta-defensins and surfactant proteins are components of the pulmonary innate immune system. Their gene expression is regulated by development, hormones, growth and immunoregulatory factors. It was our hypothesis that growth and differentiation factors such as all-trans retinoic acid (RA) and vascular endothelial growth factor (VEGF) may affect expression of selected innate immune genes by respiratory epithelial cells. Ovine JS7 cells (alveolar type II pneumocytes) were incubated in serum-free Dulbecco's modified Eagle's medium (DMEM) complete media that contained: no treatment (negative control), RA (500 nM), or VEGF (100 ng/ml) for 6, 12 or 24 h incubation. Total RNA was isolated, cDNA synthesized, and relative mRNA levels of surfactant protein A (SP-A) and SP-D, and sheep beta-defensin-1 (SBD-1) were determined by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Cells had significantly increased expression of SP-D mRNA at 6 h and 24 h, decreased expression of SP-A mRNA at 12 h, and unchanged levels of SBD-1 mRNA after the treatment with RA compared with their respective negative controls. VEGF did not alter the expression of the three innate immune genes. These findings suggest that SP-A and SP-D have different transcription regulation pathways, and that expression of SBD-1 is not inducible by RA similar to its human homolog HBD-1. The lack of changes induced by VEGF treatment suggests that VEGF does not have a direct effect on epithelial cells, but may affect gene expression indirectly.


Sujet(s)
Défensines/biosynthèse , Alvéoles pulmonaires/effets des médicaments et des substances chimiques , Surfactants pulmonaires/métabolisme , Trétinoïne/pharmacologie , Facteur de croissance endothéliale vasculaire de type A/pharmacologie , Animaux , Cellules cultivées , Défensines/génétique , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Oxadiazoles/métabolisme , Alvéoles pulmonaires/cytologie , Alvéoles pulmonaires/métabolisme , Protéine A associée au surfactant pulmonaire/biosynthèse , Protéine A associée au surfactant pulmonaire/génétique , Protéine D associée au surfactant pulmonaire/biosynthèse , Protéine D associée au surfactant pulmonaire/génétique , ARN messager/génétique , RT-PCR/méthodes , Ovis , Ovis aries
2.
Vet Pathol ; 43(5): 595-612, 2006 Sep.
Article de Anglais | MEDLINE | ID: mdl-16966437

RÉSUMÉ

The respiratory epithelium is a primary site for the deposition of microorganisms that are acquired during inspiration. The innate immune system of the respiratory tract eliminates many of these potentially harmful agents preventing their colonization. Collectins and cationic antimicrobial peptides are antimicrobial components of the pulmonary innate immune system produced by respiratory epithelia, which have integral roles in host defense and inflammation in the lung. Synthesis and secretion of these molecules are regulated by the developmental stage, hormones, as well as many growth and immunoregulatory factors. The purpose of this review is to discuss antimicrobial innate immune elements within the respiratory tract of healthy and pneumonic lung with emphasis on hydrophilic surfactant proteins and beta-defensins.


Sujet(s)
Peptides antimicrobiens cationiques/métabolisme , Collectines/métabolisme , Muqueuse respiratoire/métabolisme , Animaux
3.
Vet Pathol ; 43(5): 689-94, 2006 Sep.
Article de Anglais | MEDLINE | ID: mdl-16966446

RÉSUMÉ

Preterm and young neonates are prone to inadequate surfactant production and are susceptible to respiratory distress syndrome characterized by alveolar damage and hyaline-membrane formation. Glucocorticoid therapy is commonly used in preterm and young infants to enhance lung maturation and surfactant synthesis. Recently, vascular endothelial growth factor (VEGF) was suggested to be a novel therapeutic agent for lung maturation that lacked adverse effects in mice. The purpose of this study was to assess the safety of incremental concentration (0.0005, 0.005, and 0.05 mg/ml) and duration (16, 24, and 32 hours) of recombinant human VEGF after bronchoscopic instillation (10 ml) in neonatal lambs. High-dose VEGF caused locally extensive plum-red consolidation that was microscopically characterized by interstitial and alveolar infiltrates of cells that were morphologically and phenotypically (CD68+) consistent with monocytes/macrophages. T cells (CD3+) and B cells (CD79+) were located primarily in bronchus/bronchiole-associated lymphoid tissue and were not consistently altered by treatment with VEGF. The dose of VEGF had significant effects on both gross lesions (P < .0047) and microscopic monocyte/macrophage recruitment scores (P < .0001). Thus, the VEGF dose instilled into the lung greatly influenced cellular recruitment and lesion development. The post-dosing interval of VEGF in this study had minor impact (no statistical significance) on cellular recruitment. This study showed that airway deposition of VEGF in the neonatal lamb induces monocyte/macrophage recruitment to the lung and high doses can cause severe lesions. The cellular recruitment suggests further research is needed to define dosages that are efficacious in enhancing lung maturation while minimizing potential adverse effects.


Sujet(s)
Pneumopathie infectieuse/induit chimiquement , Facteur de croissance endothéliale vasculaire de type A/toxicité , Animaux , Animaux nouveau-nés , Poumon/anatomopathologie , Macrophages , Monocytes , Pneumopathie infectieuse/anatomopathologie , Ovis , Maladies des ovins
4.
Vet Pathol ; 42(1): 84-7, 2005 Jan.
Article de Anglais | MEDLINE | ID: mdl-15657278

RÉSUMÉ

An adult male mixed breed dog developed pain, on swallowing, that lasted for 1 week. Physical exam and radiographs revealed a subcutaneous mass in the cervical area and three metastatic nodules in the lung. The cervical mass was surgically removed and fixed in 10% buffered formalin. Histopathologic diagnosis was carcinosarcoma supported by positive immunohistochemistry (IHC) results for cytokeratin and vimentin. IHC for thyroglobulin proved that the tissue of origin was the thyroid gland. This is the fifth canine case of thyroid carcinosarcoma to be documented, but the first one to be confirmed by specific cell markers. It is an extremely rare neoplasm that also occurs in people.


Sujet(s)
Carcinosarcome/médecine vétérinaire , Maladies des chiens/anatomopathologie , Tumeurs de la thyroïde/médecine vétérinaire , Animaux , Antinéoplasiques/usage thérapeutique , Carcinosarcome/traitement médicamenteux , Carcinosarcome/métabolisme , Carcinosarcome/anatomopathologie , Maladies des chiens/traitement médicamenteux , Maladies des chiens/métabolisme , Chiens , Doxorubicine/usage thérapeutique , Issue fatale , Immunohistochimie/médecine vétérinaire , Mâle , Tumeurs de la thyroïde/traitement médicamenteux , Tumeurs de la thyroïde/métabolisme , Tumeurs de la thyroïde/anatomopathologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE